Literature DB >> 23464434

Association between EGF, TGF-β1 and TNF-α gene polymorphisms and hepatocellular carcinoma.

Hai-Zhou Shi1, Peng Ren, Qing-Jun Lu, Marco Niedrgethmnn, Guo-Yang Wu.   

Abstract

INTRODUCTION: Up to present, EGF 61*A/G, TGF-β1 -509*T/C and TNF-α -308*A/G gene polymorphisms have been analysed in other cancer entities than hepatocellular carcinoma (HCC). We here investigated the frequency of these gene polymorphisms among HCC patients.
MATERIALS AND METHODS: A total of 73 HCC patients and 117 cancer-free healthy people were recruited at the Surgical Department of Zhongshan Hospital. Genomic DNA was isolated from peripheral blood and gene polymorphisms were analyzed by PCR-RFLP.
RESULTS: The distribution of EGF 61*G/G homozygotes among HCC patients was more frequent than that in the control group (24.7% vs 11.1%, OR=2.618, 95%CI=1.195-5.738). In parallel, the frequency of the "G" allele in the HCC patient group was also higher than that in the control group (45.9% vs 33.3%, OR= 1.696, 95%CI=1.110-2.592). No difference could be found for the TGF-β1-509 and TNF-α -308 genotypes.
CONCLUSION: EGF 61*G/G genotype and G allele are significantly increased among patients with HCC. TGF-β1-509*T/C and TNF-α -308*A/G gene polymorphisms are not related to this cancer entity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23464434     DOI: 10.7314/apjcp.2012.13.12.6217

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  12 in total

Review 1.  Host nucleotide polymorphism in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Shilu Mathew; Hany Abdel-Hafiz; Abbas Raza; Kaneez Fatima; Ishtiaq Qadri
Journal:  World J Hepatol       Date:  2016-04-08

2.  Association between TGF-β1 polymorphisms and hepatocellular carcinoma risk: a meta-analysis.

Authors:  Ying Guo; Chunbao Zang; Yajun Li; Li Yuan; Qingjun Liu; Lingyan Zhang; Shaolin Li
Journal:  Genet Test Mol Biomarkers       Date:  2013-09-09

3.  Association between epidermal growth factor gene +61A/G polymorphism and the risk of hepatocellular carcinoma: a meta-analysis based on 16 studies.

Authors:  Guoping Jiang; Ke Yu; Lifang Shao; Xiaobo Yu; Chen Hu; Pei Qian; Haiyang Xie; Jinjun Li; Jie Zheng; Shusen Zheng
Journal:  BMC Cancer       Date:  2015-04-25       Impact factor: 4.430

4.  Data Mining and Systems Pharmacology to Elucidate Effectiveness and Mechanisms of Chinese Medicine in Treating Primary Liver Cancer.

Authors:  Zhen Zhang; Jun-Wei Li; Pu-Hua Zeng; Wen-Hui Gao; Xue-Fei Tian
Journal:  Chin J Integr Med       Date:  2021-08-25       Impact factor: 1.978

Review 5.  Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms.

Authors:  Mahmoud Fathy Dondeti; Eman Anwar El-Maadawy; Roba Mohamed Talaat
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

6.  The Tumor Necrosis Factor-α-308 and -238 Polymorphisms and Risk of Hepatocellular Carcinoma for Asian Populations: A Meta-Analysis.

Authors:  Qing Hu; Guo-Guang Lou; Ying-Chao Liu; Le Qian; Bo-Dong Lv
Journal:  Curr Ther Res Clin Exp       Date:  2014-09-27

7.  The association of TNF-308 (G/A) gene polymorphisms and hepatocellular carcinoma risk: a meta-analysis.

Authors:  Qing Sun; Xuedan Guo; Qi Wang; Fan Zhao
Journal:  Chin J Cancer Res       Date:  2016-10       Impact factor: 5.087

8.  Enhanced circulating transforming growth factor beta 1 is causally associated with an increased risk of hepatocellular carcinoma: a mendelian randomization meta-analysis.

Authors:  Wei-Qun Lu; Ji-Liang Qiu; Zhi-Liang Huang; Hai-Ying Liu
Journal:  Oncotarget       Date:  2016-12-20

9.  EGF rs4444903 polymorphism is associated with risk of HCV-related cirrhosis and HBV/HCV-related hepatocellular carcinoma.

Authors:  Jia Wang; Yanlin Zhong; Guixia Meng
Journal:  Int J Clin Oncol       Date:  2021-07-21       Impact factor: 3.402

Review 10.  Tumor Necrosis Factor-α-308 G/A Polymorphisms and Risk of Hepatocellular Carcinoma: A Meta-Analysis.

Authors:  Soheil Tavakolpour; Shahnaz Sali
Journal:  Hepat Mon       Date:  2016-04-12       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.